JP2025508912A - ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 - Google Patents

ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 Download PDF

Info

Publication number
JP2025508912A
JP2025508912A JP2024550866A JP2024550866A JP2025508912A JP 2025508912 A JP2025508912 A JP 2025508912A JP 2024550866 A JP2024550866 A JP 2024550866A JP 2024550866 A JP2024550866 A JP 2024550866A JP 2025508912 A JP2025508912 A JP 2025508912A
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
anle138b
fatty acids
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508912A5 (cg-RX-API-DMAC7.html
Inventor
ギーゼ，アルミン
レビン，ヨハネス
デル・ヴェスコ，エマヌエラ
Original Assignee
モダグ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モダグ ゲーエムベーハー filed Critical モダグ ゲーエムベーハー
Publication of JP2025508912A publication Critical patent/JP2025508912A/ja
Publication of JP2025508912A5 publication Critical patent/JP2025508912A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024550866A 2022-03-01 2023-03-01 ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 Pending JP2025508912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22159408.8 2022-03-01
EP22159408 2022-03-01
PCT/EP2023/055160 WO2023166045A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Publications (2)

Publication Number Publication Date
JP2025508912A true JP2025508912A (ja) 2025-04-10
JP2025508912A5 JP2025508912A5 (cg-RX-API-DMAC7.html) 2026-03-10

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550866A Pending JP2025508912A (ja) 2022-03-01 2023-03-01 ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法

Country Status (12)

Country Link
US (1) US20250161273A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486340A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508912A (cg-RX-API-DMAC7.html)
KR (1) KR20240155237A (cg-RX-API-DMAC7.html)
CN (1) CN118715010A (cg-RX-API-DMAC7.html)
AU (1) AU2023227368A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246018A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002379A1 (cg-RX-API-DMAC7.html)
IL (1) IL314952A (cg-RX-API-DMAC7.html)
MX (1) MX2024009773A (cg-RX-API-DMAC7.html)
PE (1) PE20250781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023166045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024349468A1 (en) 2023-09-26 2026-04-16 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물
WO2026139903A1 (en) 2024-12-23 2026-07-02 Teva Pharmaceutical Industries Ltd. Solid state forms of emrusolmin and process for preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714453T3 (es) * 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
KR20240155237A (ko) 2024-10-28
EP4486340A1 (en) 2025-01-08
AU2023227368A1 (en) 2024-07-18
CN118715010A (zh) 2024-09-27
US20250161273A1 (en) 2025-05-22
IL314952A (en) 2024-10-01
WO2023166045A1 (en) 2023-09-07
PE20250781A1 (es) 2025-03-14
CL2024002379A1 (es) 2025-01-24
CA3246018A1 (en) 2023-09-07
MX2024009773A (es) 2024-08-19

Similar Documents

Publication Publication Date Title
US20250161273A1 (en) Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
US20220152058A1 (en) Methods and compositions for treating various disorders
JP7761372B2 (ja) 対象におけるマイトファジーを改善するための方法
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
BR112012022336A2 (pt) composições e seus usos para tratar e/ou prevenir doença cardiovascular
KR20140101333A (ko) 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료
JP2018538273A (ja) 虚血性脳卒中を処置するための組成物および方法
MX2015001889A (es) Laquinimod para tratamiento de trastornos mediados por receptor de canabinoide tipo 1 (cb1).
US20150174118A1 (en) Use of laquinimod to delay huntington's disease progression
TW202002981A (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
WO2024210195A1 (ja) 炎症性腸疾患の治療用医薬組成物
WO2024249509A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения
HK40115748A (en) Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
KR20240004706A (ko) 신경내분비 종양을 치료하기 위한 조성물 및 방법
CN116323604A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂
CN110996937A (zh) 包含dgla的药物组合物及其用途
AU2024349468A1 (en) Emrusolmin for use in treating multiple system atrophy
CN118742299A (zh) 监测患者对视网膜氧化性疾病治疗反应的方法
CA3288236A1 (en) Pharmaceutical composition for treatment of inflammatory bowel disease
AU2023333304A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
TW201404395A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之組合治療多發性硬化症

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260227